Apellis Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $178,494 | $166,797 | $212,528 | $196,830 |
Gross Profit | 164,422 | 132,437 | 171,672 | 163,273 |
EBITDA | -30,087 | -80,389 | -24,086 | -43,864 |
EBIT | -30,533 | -80,835 | -24,533 | -44,321 |
Net Income | -42,151 | -92,225 | -36,353 | -57,445 |
Net Change In Cash | 178,494 | 166,797 | 212,528 | 196,830 |
Free Cash Flow | 4,396 | -53,418 | 19,340 | 34,096 |
Cash | 371,466 | 358,393 | 411,290 | 396,864 |
Basic Shares | 126,024 | 125,453 | 123,904 | 123,904 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $781,367 | $396,591 | $75,422 | $66,563 |
Gross Profit | 663,644 | 338,081 | 69,786 | 61,363 |
EBITDA | -154,528 | -495,211 | -617,390 | -731,269 |
EBIT | -156,325 | -496,915 | -618,877 | -732,761 |
Net Income | -197,878 | -528,628 | -652,172 | -746,354 |
Net Change In Cash | 781,367 | 396,591 | 75,422 | 66,563 |
Free Cash Flow | -88,269 | -595,508 | -515,269 | -564,229 |
Cash | 411,290 | 351,185 | 551,801 | 640,192 |
Basic Shares | 123,905 | 118,678 | 106,114 | 84,421 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.33 |
2025-03-31 | -$0.74 |
2024-12-31 | -$0.29 |
